U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on January 26, 2015, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • Chet Bush: Thank you Professor Betsy Hoza for your ‘much needed Study on the ‘impotence of...
  • Lucy: Hi Shawna – you really need to get away from your father. You also need to realise that nothing he says...
  • kazchaz: This is helpful, very much so and it would be great to hear from you again, with updates on your progress,...
  • sambo: I really need some help im so depressed and anxious I cant work or leave the house im on antidepressants and...
  • Concerned: My father was a narcissist. He basically ruined my mother’s life and she ended up dying young of...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 11324
Join Us Now!